Changes to This Summary (01/27/2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that the molecular basis for craniopharyngioma differs by histologic subtype; activating beta-catenin gene mutations are found in virtually all adamantinomatous tumors. Conversely, BRAF V600E mutations are observed in nearly all squamous papillary craniopharyngiomas (cited Sekine et al. and Brastianos et al. as references 3 and 4, respectively).
Added text to state that hypothalamic-sparing surgical techniques may show a decrease in severe postoperative obesity without an increase in tumor recurrence (cited Elowe-Gruau et al. as reference 9 and level of evidence 3iiDi).
Added text to state that it can be difficult to determine whether a tumor is progressive; carbon-11 methionine positron emission tomography is being evaluated for its use in these cases (cited Laser et al. as reference 11).
Added Clark et al. as reference 16 and level of evidence 3iiiDiii.
Added Treatment Options Under Clinical Evaluation as a new subsection.
Added Elowe-Gruau et al. as reference 2.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.